Fig. 3From: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)Changes from baseline in ABC-CFXS subscale scores. Least square mean (LSM) changes from baseline in ABC-CFXS subscale scores are shown for each treatment group along with the LSM treatment differences. A Results from the full analysis set. B Results from the patients who had ≥ 90% methylation of the promoter region of the FMR1 gene. FAS, full analysis setBack to article page